Stay updated on ADVENT-AML: Azacitidine/Venetoclax with NK Cells Clinical Trial
Sign up to get notified when there's something new on the ADVENT-AML: Azacitidine/Venetoclax with NK Cells Clinical Trial page.

Latest updates to the ADVENT-AML: Azacitidine/Venetoclax with NK Cells Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedA new history entry Revision: v3.4.2 was added and Revision: v3.4.1 removed; there are no changes to study data or status. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedAdded revision entry v3.4.1 to the record history and removed v3.4.0. This reflects an internal version update to the page rather than a change to the study data.SummaryDifference0.1%

- Check27 days agoChange DetectedUI enhancements to the study record history include a glossary display and color-coded change highlights (green for additions, red for deletions) with explanatory labels. The revision banner now shows Revision: v3.4.0, replacing the previous v3.3.4.SummaryDifference1%

- Check42 days agoChange DetectedNew revision entry v3.3.4 added and previous revision v3.3.3 removed from the history log. This reflects backend versioning changes and does not modify the study data or page functionality.SummaryDifference0.1%

- Check56 days agoChange DetectedRecord History now includes a new Study Status entry on 2025-12-30. The total number of Study Record Versions is updated to 11 on 2025-12-23, and a deletion occurred on 2025-10-01.SummaryDifference0.4%

- Check63 days agoChange DetectedFooter area now displays Revision: v3.3.3 and no longer shows HHS Vulnerability Disclosure or Revision: v3.3.2. This is a minor site maintenance change and does not affect the study record content.SummaryDifference0.2%

Stay in the know with updates to ADVENT-AML: Azacitidine/Venetoclax with NK Cells Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ADVENT-AML: Azacitidine/Venetoclax with NK Cells Clinical Trial page.